Efects of Panax ginseng in neurodegenerative diseases

Journal of Ginseng Research

Volumn 36, Issue 4, 2012, Pages 342-353

  Cho, Ik Hyun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Ginsenosides; Neurodegeneration; Neuroprotection; Panax ginseng

Indexed keywords

EID: 84867672914     PISSN: 12268453     EISSN: None     Source Type: Journal    
DOI: 10.5142/jgr.2012.36.4.342     Document Type: Review

References (98)

1. Baker JT, Borris RP, Carte B, Cordell GA, Soejarto DD, Cragg GM, Gupta MP, Iwu MM, Madulid DR, Tyler VE. Natural product drug discovery and development: new perspectives on international collaboration. J Nat Prod 1995;58:1325-1357.
2. Choi KT. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin 2008;29:1109-1118.
3. Kim MH, Lee YC, Choi SY, Cho CW, Rho J, Lee KW. The changes of ginsenoside patterns in red ginseng processed by organic acid impregnation pretreatment. J Ginseng Res 2011;35:497-503.
4. Yuan CS, Wang CZ, Wicks SM, Qi LW. Chemical and pharmacological studies of saponins with a focus on American ginseng. J Ginseng Res 2010;34:160-167.
5. Chen CF, Chiou WF, Zhang JT. Comparison of the pharmacological effects of Panax ginseng and Panax quin-quefolium. Acta Pharmacol Sin 2008;29:1103-1108.
6. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58:1685-1693.
7. Tsang D, Yeung HW, Tso WW, Peck H. Ginseng sapo-nins: influence on neurotransmitter uptake in rat brain synaptosomes. Planta Med 1985;51:221-224.
8. Rausch WD, Liu S, Gille G, Radad K. Neuroprotec-tive effects of ginsenosides. Acta Neurobiol Exp (Wars) 2006;66:369-375.
9. Nah S Y, Kim DH, Rhim H. Ginsenosides: are any of them candidates for drugs acting on the central nervous system? CNS Drug Rev 2007;13:381-404.
10. Radad K, Moldzio R, Rausch WD. Ginsenosides and their CNS targets. CNS Neurosci Ther 2011;17:761-768.
11. Djaldetti R, Lev N, Melamed E. Neuroprotection in progressive brain disorders. Isr Med Assoc J 2003;5:576-580.
12. Gerlach M, Double KL, Youdim MB, Riederer P. Strategies for the protection of dopaminergic neurons against neurotoxicity. Neurotox Res 2000;2:99-114.
13. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
14. Schapira AH. Molecular and clinical pathways to neuro-protection of dopaminergic drugs in Parkinson disease. Neurology 2009;72(7 Suppl):S44-S50.
15. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying infl ammation in neurodegenera-tion. Cell 2010;140:918-934.
16. Hu S, Han R, Mak S, Han Y. Protection against 1-methyl-4-phenylpyridinium ion (MPP+)-induced apoptosis by water extract of ginseng (Panax ginseng C.A. Meyer) in SH-SY5Y cells. J Ethnopharmacol 2011;135:34-42.
17. Van Kampen J, Robertson H, Hagg T, Drobitch R. Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease. Exp Neurol 2003;184:521-529.
18. Wang J, Xu HM, Yang HD, Du XX, Jiang H, Xie JX. Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins. Neurochem Int 2009;54:43-48.
19. Xu H, Jiang H, Wang J, Xie J. Rg1 protects the MPP+-treated MES23.5 cells via attenuating DMT1 up-regu-lation and cellular iron uptake. Neuropharmacology 2010;58:488-494.
20. Xu H, Jiang H, Wang J, Xie J. Rg1 protects iron-induced neurotoxicity through antioxidant and iron regulatory proteins in 6-OHDA-treated MES23.5 cells. J Cell Biochem 2010;111:1537-1545.
21. Rouault TA, Cooperman S. Brain iron metabolism. Semin Pediatr Neurol 2006;13:142-148.
22. Lee DW, Andersen JK. Iron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeo-stasis? J Neurochem 2010;112:332-339.
23. Chen XC, Zhou YC, Chen Y, Zhu YG, Fang F, Chen LM. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol Sin 2005;26:56-62.
24. Shi C, Zhang YX, Zhang ZF. Effect of phosphorylated-ERK1/2 on inducible nitric oxide synthase expression in the substantia nigra of mice with MPTP-induced Parkinson disease. Nan Fang Yi Ke Da Xue Xue Bao 2009;29:60-63.
25. Chen XC, Zhu YG, Zhu LA, Huang C, Chen Y, Chen LM, Fang F, Zhou YC, Zhao CH. Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. Eur J Pharmacol 2003;473:1-7.
26. Xu L, Chen WF, Wong MS. Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway. Br J Pharmacol 2009;158:738-748.
27. Wang Q, Zheng H, Zhang ZF, Zhang YX. Ginsenoside Rg1 modulates COX-2 expression in the substantia nigra of mice with MPTP-induced Parkinson disease through the P38 signaling pathway. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:1594-1598.
28. Leung KW, Yung KK, Mak NK, Chan YS, Fan TP, Wong RN. Neuroprotective effects of ginsenoside-Rg1 in primary nigral neurons against rotenone toxicity. Neurophar-macology 2007;52:827-835.
29. Liu Q, Kou JP, Yu B Y. Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-κB activation. Neurochem Int 2011;58:119-125.
30. Xu BB, Liu CQ, Gao X, Zhang WQ, Wang SW, Cao YL. Possible mechanisms of the protection of ginsenoside Re against MPTP-induced apoptosis in substantia nigra neurons of Parkinson's disease mouse model. J Asian Nat Prod Res 2005;7:215-224.
31. Lin WM, Zhang YM, Moldzio R, Rausch WD. Ginsenoside Rd attenuates neuroinfl ammation of dopaminergic cells in culture. J Neural Transm Suppl 2007;(72):105-112.
32. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545-584.
33. Tanzi RE, Bertram L. Alzheimer's disease: the latest suspect. Nature 2008;454:706-708.
34. Bazan NG, Palacios-Pelaez R, Lukiw WJ. Hypoxia signaling to genes: signifi cance in Alzheimer's disease. Mol Neurobiol 2002;26:283-298.
35. Frank B, Gupta S. A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry 2005;17:269-286.
36. Finch CE, Morgan TE. Systemic infl ammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res 2007;4:185-189.
37. Ghosh AK, Hong L, Tang J. Beta-secretase as a therapeutic target for inhibitor drugs. Curr Med Chem 2002;9:1135-1144.
38. Hills ID, Vacca JP. Progress toward a practical BACE-1 inhibitor. Curr Opin Drug Discov Devel 2007;10:383-391.
39. Imbimbo BP. Therapeutic potential of gamma-secre-tase inhibitors and modulators. Curr Top Med Chem 2008;8:54-61.
40. Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, Kim M. An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease. Eur J Neurol 2008;15:865-868.
41. Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:222-226.
42. Zhao H, Li Q, Zhang Z, Pei X, Wang J, Li Y. Long-term ginsenoside consumption prevents memory loss in aged SAMP8 mice by decreasing oxidative stress and up-regulating the plasticity-related proteins in hippocampus. Brain Res 2009;1256:111-122.
43. Tu LH, Ma J, Liu HP, Wang RR, Luo J. The neuroprotec-tive effects of ginsenosides on calcineurin activity and tau phosphorylation in SY5Y cells. Cell Mol Neurobiol 2009; 29:1257-1264.
44. Qian YH, Han H, Hu XD, Shi LL. Protective effect of ginsenoside Rb1 on beta-amyloid protein(1-42)-induced neurotoxicity in cortical neurons. Neurol Res 2009;31:663-667.
45. Xie X, Wang HT, Li CL, Gao XH, Ding JL, Zhao HH, Lu YL. Ginsenoside Rb1 protects PC12 cells against β-amyloid-induced cell injury. Mol Med Report 2010;3:635-639.
46. Zhao R, Zhang Z, Song Y, Wang D, Qi J, Wen S. Implication of phosphatidylinositol-3 kinase/Akt/glycogen synthase kinase-3β pathway in ginsenoside Rb1's attenuation of beta-amyloid-induced neurotoxicity and tau phos-phorylation. J Ethnopharmacol 2011;133:1109-1116.
47. Chen X, Huang T, Zhang J, Song J, Chen L, Zhu Y. Involvement of calpain and p25 of CDK5 pathway in ginsenoside Rb1's attenuation of beta-amyloid peptide25-35-induced tau hyperphosphorylation in cortical neurons. Brain Res 2008;1200:99-106.
48. Wang Y, Liu J, Zhang Z, Bi P, Qi Z, Zhang C. Anti-neuro-infl ammation effect of ginsenoside Rbl in a rat model of Alzheimer disease. Neurosci Lett 2011;487:70-72.
49. Li X, Zhang X, Yuan H, Quan Q. Experimental research on effect of gensenoside Rg1 on expressions of P-Tau and caspase-3 in brain slices from AD model rats. Zhongguo Zhong Yao Za Zhi 2010;35:369-372.
50. Wei CB, Jia JP, Liang P, Guan YQ. Ginsenoside-Rg1 inhibits cell apoptosis induced by beta amyloid. Zhonghua Yi Xue Za Zhi 2008;88:1763-1766.
51. Wang XY, Chen J, Zhang JT. Effect of ginsenoside Rg1 on learning and memory impairment induced by beta-amyloid peptide(25-35) and its mechanism of action. Yao Xue Xue Bao 2001;36:1-4.
52. Li WZ, Li WP, Zhang W, Yin Y Y, Sun XX, Zhou SS, Xu XQ, Tao CR. Protective effect of extract of Astragalus on learning and memory impairments and neurons' apoptosis induced by glucocorticoids in 12-month-old male mice. Anat Rec (Hoboken) 2011;294:1003-1014.
53. Shi YQ, Huang TW, Chen LM, Pan XD, Zhang J, Zhu YG, Chen XC. Ginsenoside Rg1 attenuates amyloid-beta content, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 mice. J Alzheimers Dis 2010;19:977-989.
54. Chen F, Eckman EA, Eckman CB. Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. FASEB J 2006;20:1269-1271.
55. Wang YH, Du GH. Ginsenoside Rg1 inhibits beta-secretase activity in vitro and protects against Abeta-induced cytotoxicity in PC12 cells. J Asian Nat Prod Res 2009;11:604-612.
56. Li X, Liu Y, Zhang X, Yuan H, Quan Q. Effect of ginsen-oside Rg1 on expressions of phosphory protein tau and N-methyl-D-aspartate receptor subunits NR1 and NR2B in rat brain slice model of Alzheimer's disease. Zhongguo Zhong Yao Za Zhi 2010;35:3339-3343.
57. Li X, Liu Y, Yuan HF, Quan QK. Effects of gensenoside Rg1 on tau protein phosphorylation induced by okadaic acid in rat brain slices. Zhong Xi Yi Jie He Xue Bao 2010;8:955-960.
58. Gong YS, Zhang JT. Effect of 17-beta-estradiol and ginsenoside Rg1 on reactive microglia induced by beta-amyloid peptides. J Asian Nat Prod Res 1999;1:153-161.
59. Joo SS, Won TJ, Lee DI. Reciprocal activity of ginsen-osides in the production of proinflammatory repertoire, and their potential roles in neuroprotection in vivo. Planta Med 2005;71:476-481.
60. Li N, Liu B, Dluzen DE, Jin Y. Protective effects of gin-senoside Rg2 against glutamate-induced neurotoxicity in PC12 cells. J Ethnopharmacol 2007;111:458-463.
61. Zhang G, Liu A, Zhou Y, San X, Jin T, Jin Y. Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia. J Ethnopharmacol 2008;115:441-448.
62. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007;184:69-91.
63. Joo SS, Lee DI. Potential effects of microglial activation induced by ginsenoside Rg3 in rat primary culture: enhancement of type A Macrophage Scavenger Receptor expression. Arch Pharm Res 2005;28:1164-1169.
64. Yang L, Hao J, Zhang J, Xia W, Dong X, Hu X, Kong F, Cui X. Ginsenoside Rg3 promotes beta-amyloid peptide degradation by enhancing gene expression of neprilysin. J Pharm Pharmacol 2009;61:375-380.
65. Shieh PC, Tsao CW, Li JS, Wu HT, Wen YJ, Kou DH, Cheng JT. Role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the action of ginsenoside Rh2 against beta-amyloid-induced inhibition of rat brain astro-cytes. Neurosci Lett 2008;434:1-5.
66. Hwang SH, Shin TJ, Choi SH, Cho HJ, Lee BH, Pyo MK, Lee JH, Kang J, Kim HJ, Park CW et al. Gintonin, newly identified compounds from ginseng, is novel ly-sophosphatidic acids-protein complexes and activates G protein-coupled lysophosphatidic acid receptors with high affi nity. Mol Cells 2012;33:151-162.
67. Hwang SH, Shin EJ, Shin TJ, Lee BH, Choi SH, Kang J, Kim HJ, Kwon SH, Jang CG, Lee JH et al. Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing. J Alzheim-ers Dis 2012; Epub ahead of print.
68. Damiano M, Galvan L, Deglon N, Brouillet E. Mitochondria in Huntington's disease. Biochim Biophys Acta 2010;1802:52-61.
69. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;72:971-983.
70. Ryu JK, Kim SU, McLarnon JG. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease. Exp Neurol 2004;187:150-159.
71. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P. Imaging microglial activation in Huntington's disease. Brain Res Bull 2007;72:148-151.
72. Leegwater-Kim J, Cha JH. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. NeuroRx 2004;1:128-138.
73. Kim JH, Kim S, Yoon IS, Lee JH, Jang BJ, Jeong SM, Lee JH, Lee BH, Han JS, Oh S et al. Protective effects of ginseng saponins on 3-nitropropionic acid-induced striatal degeneration in rats. Neuropharmacology 2005;48:743-756.
74. Wu J, Jeong HK, Bulin SE, Kwon SW, Park JH, Bez-prozvanny I. Ginsenosides protect striatal neurons in a cellular model of Huntington's disease. J Neurosci Res 2009;87:1904-1912.
75. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hy-man BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181-4192.
76. Borlongan C V, Koutouzis TK, Sanberg PR. 3-Nitropropi-onic acid animal model and Huntington's disease. Neuro-sci Biobehav Rev 1997;21:289-293.
77. Kim SU, de Vellis J. Microglia in health and disease. J Neurosci Res 2005;81:302-313.
78. Park JS, Park EM, Kim DH, Jung K, Jung JS, Lee EJ, Hyun JW, Kang JL, Kim HS. Anti-infl ammatory mechanism of ginseng saponins in activated microglia. J Neuro-immunol 2009;209:40-49.
79. Jung JS, Shin JA, Park EM, Lee JE, Kang YS, Min SW, Kim DH, Hyun JW, Shin C Y, Kim HS. Anti-infl ammato-ry mechanism of ginsenoside Rh1 in lipopolysaccharide-stimulated microglia: critical role of the protein kinase A pathway and hemeoxygenase-1 expression. J Neurochem 2010;115:1668-1680.
80. Mulder DW. Clinical limits of amyotrophic lateral sclerosis. Adv Neurol 1982;36:15-22.
81. Nagai M, Aoki M, Miyoshi I, Kato M, Pasinelli P, Ka-sai N, Brown RH Jr, Itoyama Y. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci 2001;21:9246-9254.
82. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006;312:1389-1392.
83. Pasinelli P, Houseweart MK, Brown RH Jr, Cleveland DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2000;97:13901-13906.
84. Rowland LP. Amyotrophic lateral sclerosis: theories and therapies. Ann Neurol 1994;35:129-130.
85. Ferraiuolo L, Heath PR, Holden H, Kasher P, Kirby J, Shaw PJ. Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J Neurosci 2007;27:9201-9219.
86. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009;4:3.
87. Jiang F, DeSilva S, Turnbull J. Benefi cial effect of ginseng root in SOD-1 (G93A) transgenic mice. J Neurol Sci 2000;180:52-54.
88. Li YG, Ji DF, Zhong S, Shi LG, Hu GY, Chen S. Saponins from Panax japonicus protect against alcohol-induced hepatic injury in mice by up-regulating the expression of GPX3, SOD1 and SOD3. Alcohol Alcohol 2010;45:320-331.
89. Kim YH, Park KH, Rho HM. Transcriptional activation of the Cu, Zn-superoxide dismutase gene through the AP2 site by ginsenoside Rb2 extracted from a medicinal plant, Panax ginseng. J Biol Chem 1996;271:24539-24543.
90. Liu DH, Chen YM, Liu Y, Hao BS, Zhou B, Wu L, Wang M, Chen L, Wu WK, Qian XX. Ginsenoside Rb1 reverses H2O2-induced senescence in human umbilical endothe-lial cells: involvement of eNOS pathway. J Cardiovasc Pharmacol 2012;59:222-230.
91. Conway DS, Cohen JA. Multiple sclerosis: mechanisms of disability accumulation in multiple sclerosis. Nat Rev Neurol 2010;6:654-655.
92. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol 2010;9:299-308.
93. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC. Linomide in relapsing and secondary progressive MS. Part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000;54:1726-1733.
94. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006;60:12-21.
95. Kieseier BC, Wiendl H. Oral disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs 2007;21:483-502.
96. Lee YS, Chung IS, Lee IR, Kim KH, Hong WS, Yun YS. Activation of multiple effector pathways of immune system by the antineoplastic immunostimulator acidic polysaccharide ginsan isolated from Panax ginseng. Anti-cancer Res 1997;17:323-331.
97. Hwang I, Ahn G, Park E, Ha D, Song JY, Jee Y. An acidic polysaccharide of Panax ginseng ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells. Immunol Lett 2011;138:169-178.
98. Kim E, Cameron M, Lovera J, Schaben L, Bourdette D, Whitham R. American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study. Mult Scler 2011;17:1523-1526.